Chronix Biomedical,  
Chronix生物医学公司是一家分子诊断学公司，主要开发癌症的血液测试，包括伴随诊断和用于检测微小残留病的测试。Chronix生物医学公司正在准备通过它自己的CLIA认证实验室提供它的开创性的测试。该公司的最初产品是将会被癌症治疗中心和肿瘤学家在治疗癌症病人的时候使用的一种测试。Chronix生物医学公司是一家私营公司，总部设在加利福尼亚州的圣何塞，实验室设在德国哥廷根以及美国南达科他州的布鲁金斯。它是第一家对无细胞DNA使用下一代测序技术的公司。该公司拥有两个检测无细胞DNA和RNA的已批准的专利，以及使用下一代测序技术用于检测乳腺癌、前列腺癌和结直肠癌的4个正在申请的专利。

Chronix Biomedical, Inc. is a molecular diagnostics company developing blood tests primarily for monitoring minimal residual disease (MRD) in cancer patients. Chronix will offer its pioneering tests through its own CLIA certified laboratories expected to open in 2015. The value proposition of the Chronix MRD test is that it:
1) Reduces costs by saving money on unnecessary treatments and more importantly treating cancer recurrences earlier in patients.
2) Improves quality in healthcare by treating a patients recurrences of cancer as earlier as possible. In addition, it eliminates unnecessary treatments to patients.
3) Increases access to healthcare because a patient can have their blood drawn at any blood-drawing station or in their physician's office and sent to the Chronix laboratory.
Chronix is privately held with headquarters in San Jose, California, and laboratories in Göttingen, Germany and Brookings, South Dakota.